# Spectral AI, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Spectral AI, Inc.). ## Overview Spectral AI, Inc. is a U.S.-based medical technology company focused on artificial intelligence for wound assessment and burn evaluation. Its core platform, DeepView System, combines imaging hardware with software intended to support clinical decision-making in healthcare and military settings through its operating company and related subsidiaries. ## Products & services • DeepView System imaging device • AI-based wound and burn assessment software • Software-as-a-medical-device (SaMD) licensing • Image hosting, maintenance, and algorithm updates • Research and development services under government contracts - **DeepView System hardware** (35%) — Proprietary imaging device platform used to capture clinical images for AI analysis. - **SaMD / software licensing** (25%) — Software licensing for DeepView System, including access to algorithm updates and hosting. - **Government R&D contracts** (40%) — Applied research and development work tied to BARDA, MTEC, and DHA programs. - DeepView System imaging device - AI-based wound and burn assessment software - Software-as-a-medical-device (SaMD) licensing - Image hosting, maintenance, and algorithm updates - Research and development services under government contracts ## Customers Spectral AI sells primarily to government and defense-related research customers today, with BARDA, MTEC, and DHA supporting development of the DeepView System for burn evaluation. Its commercial model is aimed at hospitals, clinics, and site-of-service providers that would use the platform for wound and burn assessment once broadly deployed. - **U.S. government research agencies** (primary) — BARDA, MTEC, and DHA fund DeepView development for burn and battlefield applications. - **Military and defense medical users** (primary) — Military healthcare programs use handheld burn evaluation tools in field and trauma settings. - **Hospitals and burn centers** (secondary) — Clinical sites would buy DeepView for wound and burn assessment and treatment support. - **Clinics and site-of-service providers** (secondary) — Outpatient and point-of-care settings would use the system for faster triage and workflow support. - U.S. government agencies funding burn and battlefield evaluation work - Defense and military medical programs using handheld assessment tools - Hospitals and burn centers that would adopt clinical decision support - Clinics and site-of-service providers needing faster wound triage - Future software customers paying recurring licensing fees ## Geography The company is headquartered in the United States and its disclosed contract activity is centered on U.S. government programs. Its commercial pricing is intended to be set by country and site of service, indicating a future multi-market rollout rather than a single domestic-only model. - United States is the core operating and contracting base - Government-funded development work is tied to U.S. agencies - Commercial pricing is planned by country and site of service - Future adoption could expand beyond the U.S. healthcare market - No country revenue breakdown was disclosed in the excerpts ## Strategy Spectral AI’s strategy is to convert DeepView from a development-stage platform into a commercial product with both device and recurring software revenue. The company is also building a healthcare-focused AI intellectual property portfolio through Spectral IP, while using government contracts to validate the burn indication and support product development. - **Commercialize DeepView System** (medium-term) — Moves the company from contract-funded development toward product sales and software licensing. - **Advance burn indication validation** (short-term) — Clinical and military validation supports adoption and reimbursement discussions. - **Expand healthcare AI IP portfolio** (medium-term) — Additional intellectual property can strengthen differentiation and optionality. - Commercialize DeepView as both device and software - Use government contracts to validate clinical use cases - Build recurring revenue through SaMD licensing - Expand the AI intellectual property portfolio via Spectral IP - Price by country and site of service to improve adoption ## Risks The business depends on successful clinical validation, regulatory acceptance, and eventual commercial adoption of a novel AI-enabled medical device platform. It also relies heavily on government-funded development programs, so delays, milestone failures, or changes in public-sector funding can materially affect execution and revenue visibility. - **Dependence on government contract funding** [high] — A large share of current activity is tied to BARDA, MTEC, and DHA programs with milestone-based funding. - **Clinical validation and adoption risk** [high] — DeepView must prove accuracy and utility before broad hospital and military adoption. - **Regulatory and reimbursement uncertainty** [medium] — Medical software and imaging products may face approval, labeling, and reimbursement hurdles. - **Early-stage commercialization risk** [high] — The company is still transitioning from development contracts to product revenue. - Commercial adoption risk for a new medical AI platform - Regulatory and clinical validation risk for burn indications - Dependence on government grants and contract milestones - Execution risk in converting R&D into recurring revenue - Valuation and funding risk typical of early-stage medtech ## Accounting Revenue recognition is a key issue because the company records research and development revenue from government contracts, which may depend on milestones, deliverables, and contract terms. Investors should also watch fair value estimates for warrant liabilities, debt, stock-based compensation, and valuation allowances, since these judgments can materially affect reported results in a development-stage company. - **Revenue recognition on government contracts** — Research and development revenue - **Warrant liabilities** — Other income/expense and net loss - **Fair value of debt and stock-based compensation** — Operating and non-operating results - **Income tax valuation allowances** — Tax provision and balance sheet - Government contract revenue recognition depends on milestones and deliverables - Milestone-based grants can create quarter-to-quarter revenue volatility - Warrant liabilities require fair value remeasurement - Fair value of debt and stock compensation affects reported expenses - Inventory, ROU assets, and tax valuation allowances rely on estimates --- *Last updated: 2026-04-29T04:59:44.627496+00:00*